Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Inotiv, Inc.
  6. News
  7. Summary
    NOTV   US45783Q1004

INOTIV, INC.

(NOTV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

INOTIV, INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)

09/28/2021 | 05:03pm EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 27, 2021, Inotiv, Inc. (the "Company") and Joseph E. Flynn, the Company's former Chief Commercial Officer, entered into an agreement (the "Separation and Release Agreement") in connection with the termination of Mr. Flynn's employment on September 8, 2021. Under the terms of the Separation and Release Agreement, (i) the Company will pay Mr. Flynn a severance benefit in the form of salary continuation for a period of four months, (ii) Mr. Flynn will be entitled to exercise 7,000 outstanding stock options until the earlier of October 8, 2021 or the expiration date of such stock options and will forfeit all of his unvested stock options and restricted stock awards, (iii) the Company will reimburse Mr. Flynn an amount equal to his monthly COBRA premium for a period of four months after September 30, 2021, provided that such payments will cease should he become entitled to other health insurance, and (iv) the Company agreed to reduce Mr. Flynn's existing post-employment non-solicitation obligations from 24 months to six months and to limit those obligations to customers or entities with whom Mr. Flynn had contact.

As consideration for receiving the payments under the Separation and Release Agreement, Mr. Flynn agreed to release substantially all claims against the Company. The Separation and Release Agreement also (i) prohibits Mr. Flynn and the Company from disparaging each other, (ii) includes a covenant not to sue (iii) during the period in which Mr. Flynn receives severance benefits, generally requires Mr. Flynn to provide reasonable assistance to the Company with transitional matters relating to his former duties and (iv) reaffirms existing covenants and obligations and the rights and remedies of the Company regarding confidentiality, restrictive covenants and the assignment of inventions.

Mr. Flynn has seven calendar days from September 26, 2021 (the date he signed the Separation and Release Agreement) to revoke the Separation and Release Agreement, and the Separation and Release Agreement provides that the terms thereof, including the Company's obligations to provide the severance benefits described above, will not become effective until the eighth calendar day after the date the agreement was executed by Mr. Flynn.

The foregoing summary of the Separation and Release Agreement does not purport to be complete and is qualified in its entirety by reference to the Separation and Release Agreement, a copy of which will be filed with the Company's Form 10-K for the year ended September 30, 2021.

Item 8.01 Other Events.

As previously announced, the Company entered into, and subsequently closed the transactions related to, an Agreement and Plan of Merger to acquire Bolder BioPATH, Inc. and an Asset Purchase Agreement to acquire the business of HistoTox Labs, Inc. Exhibits 99.1 and 99.2 hereto provide certain historical financial statements for Bolder BioPATH, Inc. and HistoTox Labs, Inc., respectively.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits


99.1 Unaudited financial statements of Bolder BioPATH, Inc. as of and for the

three months ended March 31, 2021 and the unaudited balance sheet of Bolder

BioPATH, Inc. as of December 31, 2020, together with the notes thereto. 99.2 Unaudited financial statements of HistoTox Labs, Inc. as of and for the

three months ended March 31, 2021 and the unaudited balance sheet of

HistoTox Labs, Inc. as of December 31, 2020, together with the notes

thereto.

104 Cover page interactive data file (embedded within the inline XBRL document).








                                     - 2 -

© Edgar Online, source Glimpses

All news about INOTIV, INC.
01/13INOTIV : Announces Expansion of Safety Assessment Offerings with Acquisition of Integrated..
PU
01/13INOTIV, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial ..
AQ
01/10Inotiv, Inc. Announces Expansion of Safety Assessment Offerings with Acquisition of Int..
AQ
01/10Inotiv, Inc. acquired Integrated Laboratory Systems, Inc. from Sier Capital for $52.8 m..
CI
01/06Inotiv Purchases Robinson Services' Rabbit Breeding, Supply Business for Undisclosed Su..
MT
01/06Inotiv, Inc. Announces the Acquisition of the Rabbit Breeding and Supply Business of Ro..
AQ
01/06Inotiv, Inc. acquired Rabbit Breeding and Supply Business of Robinson Services Inc.
CI
01/04Inotiv to Collaborate With Synexa Life Sciences to Develop Biomarker, Biotherapeutic So..
MT
01/04Inotiv, Inc. and Synexa Life Sciences Sign Letter of Intent to Establish Center of Exce..
AQ
01/04Inotiv, Inc. and Synexa Life Sciences Sign Letter of Intent to Establish Center of Exce..
CI
More news
Analyst Recommendations on INOTIV, INC.
More recommendations
Financials (USD)
Sales 2022 433 M - -
Net income 2022 25,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 26,7x
Yield 2022 -
Capitalization 679 M 679 M -
Capi. / Sales 2022 1,57x
Capi. / Sales 2023 1,31x
Nbr of Employees 554
Free-Float 66,6%
Chart INOTIV, INC.
Duration : Period :
Inotiv, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INOTIV, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 27,51 $
Average target price 65,00 $
Spread / Average Target 136%
EPS Revisions
Managers and Directors
Robert Leasure President, Chief Executive Officer & Director
Beth A. Taylor Chief Financial Officer & Vice President-Finance
Gregory C. Davis Chairman
Andrew Bowen Senior Director-Information Technology
R. Matthew Neff Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INOTIV, INC.-34.61%679
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331
ICON PUBLIC LIMITED COMPANY-17.37%20 831